ABSTRACT
Importance of inositols and inositol isomer ratios in therapy to improve metabolic and hormonal profile and fertility in women
Inositols, which, chemically, are cyclic sugar alcohols, are important regulators of metabolic and hormone-mediated processes. Particularly important for clinical practice are two most frequently investigated isomers: myo-inositol (MYO) and D-chiro-inositol (DCI). Both play a role in glucose and lipid metabolism, regulation of the menstrual cycle and enhancement of the quality of ova. Inositol supplementation is useful particularly in the treatment of polycystic ovary syndrome (PCOS). Inositols have been shown to improve metabolic and hormonal status in women with PCOS and also restore spontaneous ovulation. Inositol also improves the efficacy of ovarian stimulation in assisted reproduction techniques (ART).
Piśmiennictwo
1. Dinicola S, Chiu TT, Unfer V, et al. The rationale of the myo-inositol and D-chiro-inositol combined treatment for polycystic ovary syndrome. J Clin Pharmacol 2014 Oct;54(10):1079-92
2. Laganà AS, Garzon S, Casarin J, et al. Inositol in polycystic ovary syndrome: restoring fertility through a pathophysiology-based approach. Trends Endocrinol Metab 2018;29(11):768-80
3. Monastra G, Unfer V, Harrath AH, et al. Combining treatment with myo-inositol and D-chiro-inositol (40:1) is effective in restoring ovary function and metabolic balance in PCOS patients. Gynecol Endocrinol 2017;33(1):1-9
4. Jonard S, Dewailly D. The follicular excess in polycystic ovaries, due to intra-ovarian hyperandrogenism, may be the main culprit for the follicular arrest. Hum Reprod Update 2004;10(2):107-17
5. Unfer V. D-Chiro-inositol in PCOS: the myths and what we know about the reality. Int J Food Sci Nutr 2022;73(7):989-91
6. Thomas RM, Nechamen CA, Mazurkiewicz JE, et al. The adapter protein APPL1 links FSH receptor to inositol 1,4,5-trisphosphate production and is implicated in intracellular Ca(2+) mobilization. Endocrinology 2011;152(4):1691-701
7. Grasberger H, van Sande J, Hag-Dahood Mahameed A, et al. A familial thyrotropin (TSH) receptor mutation provides in vivo evidence that the inositol phosphates/Ca2+ cascade mediates TSH action on thyroid hormone synthesis. J Clin Endocrinol Metab 2007;92(7):2816-20
8. Heimark D, McAllister J, Larner J. Decreased myo-inositol to chiro-inositol (M/C) ratios and increased M/C epimerase activity in PCOS theca cells demonstrate increased insulin sensitivity compared to controls. Endocr J 2014;61(2):111-7
9. Unfer V, Carlomagno G, Papaleo E, et al. Hyperinsulinemia alters myoinositol to d-chiroinositol ratio in the follicular fluid of patients with PCOS. Reprod Sci 2014;21(7):854-8
10. Nestler JE, Jakubowicz DJ, de Vargas AF, et al. Insulin stimulates testosterone biosynthesis by human thecal cells from women with polycystic ovary syndrome by activating its own receptor and using inositolglycan mediators as the signal transduction system. J Clin Endocrinol Metab 1998;83(6):2001-5
11. Carlomagno G, Unfer V, Roseff S. The D-chiro-inositol paradox in the ovary. Fertil Steril 2011;95(8):2515-6
12. Unfer V, Carlomagno G, Rizzo P, et al. Myo-inositol rather than D-chiro-inositol is able to improve oocyte quality in intracytoplasmic sperm injection cycles. A prospective, controlled, randomized trial. Eur Rev Med Pharmacol Sci 2011;15(4):452-7
13. Benelli E, Del Ghianda S, Di Cosmo C, et al. A combined therapy with myo-inositol and D-chiro-inositol improves endocrine parameters and insulin resistance in PCOS young overweight women. Int J Endocrinol 2016;2016:3204083
14. Unfer V, Facchinetti F, Orrù B, et al. Myo-inositol effects in women with PCOS: a meta-analysis of randomized controlled trials. Endocr Connect 2017;6(8):647-58
15. Genazzani AD, Lanzoni C, Ricchieri F, et al. Myo-inositol administration positively affects hyperinsulinemia and hormonal parameters in overweight patients with polycystic ovary syndrome. Gynecol Endocrinol 2008;24(3):139-44
16. Chiu TT, Rogers MS, Briton-Jones C, et al. Effects of myo-inositol on the in-vitro maturation and subsequent development of mouse oocytes. Hum Reprod 2003;18(2):408-16
17. Chiu TT, Rogers MS, Law EL, et al. Follicular fluid and serum concentrations of myo-inositol in patients undergoing IVF: relationship with oocyte quality. Hum Reprod 2002;17(6):1591-6
18. Laganà AS, Barbaro L, Pizzo A. Evaluation of ovarian function and metabolic factors in women affected by polycystic ovary syndrome after treatment with D-Chiro-Inositol. Arch Gynecol Obstet 2015;291(5):1181-6
19. Dinicola S, Unfer V, Facchinetti F, et al. Inositols: from established knowledge to novel approaches. Int J Mol Sci 2021;22(19):10575
20. Armijo-Sánchez A, Benítez Castillo N, García-Vidal E, et al. Treatment with a patented 3.6:1 myo-inositol to D-chiro-inositol ratio, antioxidants, vitamins and minerals food supplement in women with a history of assisted reproductive technique (ART) failures: a series of case reports. Clin Med Insights Case Rep 2024;17:11795476241242265
21. Mendoza N, Diaz-Ropero MP, Aragon M, et al. Comparison of the effect of two combinations of myo-inositol and D-chiro-inositol in women with polycystic ovary syndrome undergoing ICSI: a randomized controlled trial. Gynecol Endocrinol 2019;35(8):695-700
22. Isabella R, Raffone E. CONCERN: does ovary need D-chiro-inositol? J Ovarian Res 2012;5(1):14
23. Zheng W, Nagaraju G, Liu Z, et al. Functional roles of the phosphatidylinositol 3-kinases (PI3Ks) signaling in the mammalian ovary. Mol Cell Endocrinol 2012;356(1-2):24-30
24. Mendoza N, Galan MI, Molina C, et al. High dose of d-chiro-inositol improves oocyte quality in women with polycystic ovary syndrome undergoing ICSI: a randomized controlled trial. Gynecol Endocrinol 2020;36(5):398-401
